LQDA vs AVDL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AVDL Captures Institutional Edge (3โ1 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avadel Pharmaceuticals plc Ordinary Share (AVDL) driven by superior Valuation, Momentum & Technical, Options & Structure while LQDA counters with relative strength in Growth & Margin. Fundamentally, LQDA trades at 15.8x Forward P/E with 47.1% operating margin (+314.6% YoY revenue) versus AVDL at 28.8x Forward P/E and 2.5% operating margin (+54.9% YoY). In options structure, LQDA sits in BREAKDOWN (9th %ile IV; Dealer Gamma Walls on Pro) against AVDL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LQDA | AVDL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $5.1B | $2.1B | Larger Scale | LQDA |
| Trailing P/E Ratio Valuation | 18.2x | 16.8x | Lower Multiple | AVDL |
| Forward P/E Ratio Valuation | 15.8x | 28.8x | Lower Multiple | LQDA |
| Revenue Growth (YoY) Growth | +314.6% | +54.9% | Higher Growth | LQDA |
| Operating Margin (TTM) Profitability | 47.1% | 2.5% | Higher Margin | LQDA |
| Net Profit Margin Profitability | -15.2% | -0.1% | Higher Margin | AVDL |
| Return on Equity (ROE) Capital Efficiency | 131.8% | -0.3% | Higher ROE | LQDA |
| 52-Week Range Position Momentum | 45% ($22โ$94) | 89% ($6โ$24) | Stronger Trend | AVDL |
| Beta / 30D Volatility Risk Regime | 1.00ฮฒ ยท 76% Vol | 0.14ฮฒ ยท 2% Vol | Lower Realized Risk | AVDL |
| Unified Institutional Score Composite Signal | 26.6 / 100 (SELL) | 62.9 / 100 (BUY) | Higher Composite | AVDL |